Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer

NCT00924807 is registered in ClinicalTrials.gov with Beth Israel Medical Center as lead sponsor.

NCT NCT00924807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00924807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer
Lead sponsor
Beth Israel Medical Center
Phase
Phase 1/2
Overall status
Terminated
Start date
September 30, 2008
Completion date
December 31, 2013
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer